PRODUCT DETAILS VIEW ALL PRODUCTS

Allercet M Kid Tablets (Montelukast + Levocetirizine Dispersible)

  • Montelukast 4 mg, Levocetirizine dihydrochloride IP 2.5 mg Dispersible Tablets.
  • Indicated for treatment of allergic rhinitis.
  • Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics.
  • Children aged 6 to 12 years: One tablet, once daily or as recommended by the physician.
  • Contraindicated in patients with known hypersensitivity to montelukast, levocetirizine, to other piperazine derivatives or to any of the excipients. Allercet M Kid tablet should not be administered in children with impaired renal function. Children 6 to 11 years of age with renal impairment.
  • Neuropsychiatric events have been reported in patients taking montelukast. Monitor closely and instruct patients to be alert for neuropsychiatric events.
  • Allercet-M KID may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma.
  • Dyspepsia, abdominal pain, rash, dizziness, headache, fatigue, fever, trauma, cough, nasal congestion, somnolence, fatigue, nasopharyngitis, dry mouth, and pharyngitis.
  • Anti-Allergics